2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 255

Safety and Efficacy of Long-Term Canakinumab Therapy in Patients with CAPS: Final Results from Beta-Confident Registry
Abstract Number: 739

Safety and Efficacy of Rituximab in the Treatment of Refractory Systemic Lupus Erythematosus: Results from a National Register
Abstract Number: 3033

Safety and Efficacy of Single Dose VAY736 (anti-BAFF-R mAb) in Patients with Primary Sjögren’s Syndrome (pSS)
Abstract Number: 969

Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial
Abstract Number: 721

Safety and Efficacy of Switching from Originator to CT-P13 Infliximab Biosimilar in Patients Affected By Spondyloarthritis. a 6-Month Observational Study
Abstract Number: 385

Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease
Abstract Number: 330

Safety of Denosumab in Postmenopausal Osteoporosis and in Cancer and Bone Metastase Treatment: A Systematic Review and Meta-Analysis
Abstract Number: 2625

Safety of Multiple Retreatments with Rituximab in Real Life: Long Term Registry Data from 1984 Patients with Rheumatoid Arthritis
Abstract Number: 1624

Safety of Surgery in Patients Treated with Tocilizumab for Rheumatoid Arthritis : Data from a French Registry
Abstract Number: 2641

Safety of Synthetic and Biological Dmards: Slr Informing the Update of the EULAR Recommendations for the Management of RA
Abstract Number: 3000

Safety of the Knee Needle Arthroscopy: A Review of 1136 Procedures in 919 Patients
Abstract Number: 2622

Safety, Pharmacokinetics, and Biomarker Profile from Phase 1 Clinical Trials of Healthy Volunteers Treated with GDC-0853, a Highly Selective Reversible Oral Bruton’s Tyrosine Kinase (BTK) Inhibitor
Abstract Number: 144

Safety, Tolerability and Feasibility of Minimally Invasive Ultrasound-Guided Synovial Biopsyof Wrist and Metacarpophalangeal Joints – an Ultrasound Follow-up Study
Abstract Number: 1610

Safety, Tolerability, and Dose-Dependent Inhibition of T-Cell-Dependent Antibody Response with MEDI4920, a Novel, Engineered CD40L Antagonist: Results of a Single-Ascending Dose Study in Healthy Volunteers
Abstract Number: 665

Salivary Gland Secretome: A Novel Tool to Identify Biomarkers of Dryness and Immunopathology in Primary Sjogren’s Syndrome and Non-Autoimmune Sicca Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].